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Introduction {#sec1}
============

The dopamine transporter (DAT) is responsible for the reuptake of dopamine into presynaptic terminals and is responsible for the termination of dopamine\'s effect. Because altered dopamine signaling in the brain has been associated with a host of disorders, including Parkinson disease, schizophrenia, bipolar disease, and attention deficit disorder, DAT function has been the focus of genetic studies in several species. In humans, loss of function of DAT causes infantile Parkinson disease, with dystonia, rigidity, bradykinesia, and tremor. Complete loss of function leads to onset in infancy, delayed in some cases until adolescence when there is partial loss of function ([@bib21], [@bib22], [@bib28]). DAT deficiency is a rare disorder, but believed to be underdiagnosed ([@bib28]), and there is no effective therapy. DAT coding variants have been associated with attention-deficit/hyperactivity disorder (ADHD) ([@bib26]), and polymorphisms in the DAT gene (SLC6A3) have been associated with treatment-resistant schizophrenia ([@bib3]). Loss-of-function mutation of the DAT gene in mice ([@bib10], [@bib15]) and *Drosophila* ([@bib2]) causes hyperlocomotion and disordered sleep. In mice, this is associated with reduced levels of releasable dopamine and prolongation of its clearance from the extracellular space ([@bib10]). DAT-mutant mice have been used as models for ADHD and schizophrenia because of the genetic associations, behaviors, and responses to pharmacological agents ([@bib32]).

We find here that zebrafish with mutation of the gene encoding DAT (*slc6a3*) hover near the bottom of the tank. We find loss of tyrosine hydroxylase (TH)-immunoreactive neurons, specifically in the A8 midbrain region of the mutant fish. The atypical antipsychotic clozapine, functioning in part through blocking of D2 receptors, reverses the behavioral defect and restores neuronal integrity in the A8 region. RNA sequencing (RNA-seq) analysis indicates that clozapine increases the expression of erythropoietin pathway genes, and transgenic over-expression of Epoa partially rescues the behavior. This suggests that the clozapine function in DAT-mutant fish is at least in part due to the restoration of midbrain TH+ neurons and that it may do so at least in part by upregulating erythropoietin expression.

Results {#sec2}
=======

Fish with Dopamine Transporter Deficiency Display Repetitive Bottom Swimming Behavior {#sec2.1}
-------------------------------------------------------------------------------------

We generated two independent alleles of *slc6a3−/−* using CRISPR/Cas9 technology ([Figures 1](#fig1){ref-type="fig"}A and [S1](#mmc1){ref-type="supplementary-material"}, [Table 1](#tbl1){ref-type="table"}). Both cause a predicted frameshift and early termination of protein translation ([Figure S1](#mmc1){ref-type="supplementary-material"}). In addition, allele 1, carrying 7-bp deletion in exon10, has markedly reduced *slc6a3* mRNA, presumably from nonsense-mediated mRNA decay ([Figure 1](#fig1){ref-type="fig"}B, [Table 2](#tbl2){ref-type="table"}). Beginning around 6 weeks post fertilization, *slc6a3−/−* fish adopt a posture with their bodies at an angle pointing toward the tank bottom ([Figures 1](#fig1){ref-type="fig"}C--1E, [Videos S1](#mmc3){ref-type="supplementary-material"}, [S2](#mmc4){ref-type="supplementary-material"}, and [S3](#mmc5){ref-type="supplementary-material"}) and hover toward the bottom of the tank consistently, rarely leaving the lower part of the tank ([Figures 1](#fig1){ref-type="fig"}E--1G), although they are fully capable of swimming toward the top of the tank to garner food (data not shown). The fish move back and forth from the bottom of the tank, a behavior reminiscent of the "digging" described previously by Tinbergen and Schemmel in other fish species ([@bib35], [@bib38]). The *slc6a3−/−* fish have normal swimming capability, although the allele2 fish manifest a slight reduction of swimming speed compared with the wild-type ([Figure S3](#mmc1){ref-type="supplementary-material"}A). The tendency for *slc6a3−/−* fish to dwell toward the bottom of the tank has recently been reported by others ([@bib19]). The *slc6a3−/−* fish otherwise are indistinguishable from wild-type in terms of morphology, size, and development ([Figure S2](#mmc1){ref-type="supplementary-material"}). Both alleles manifest reduction of spawning rates compared with wild-type: 72% (78 of 109 trials), *slc6a3−/− allele 1*: 38% (26 of 68 trials), *slc6a3−/− allele2*: 42% (10 of 24 trials).Figure 1*slc6a3* Deficiency Causes Repetitive Behavior(A) The wild-type *Slc6a3* protein structure and two different alleles obtained by CRISPR deletions resulting in truncation at different domains in *Slc6a3* proteins.(B) qPCR indicating dramatic reduction of *slc6a3* truncated mRNA in *slc6a3−/−* allele1 when compared with the wild-type.(C) The behavior recording system.(D) Heatmaps of fish trajectory of wild-type and two alleles of *slc6a3*−/− in the home tank in a 30-min video (60 frames per second). The heatmap colors represent frames that fish appear within each 5 × 5-pixel bin in the image (1224 × 500 pixel in 30 min).(E) The "digging" behavior in the *slc6a3*−/− fish compared with wild-type. All 1-s videos show fish at the tank bottom. Fish bearing both *slc6a3−/−* alleles display a persistent "digging" behavior, whereas wild-type fish do not.(F) The quantification of average swimming height of fish (n~WT~ = 64, n~*slc6a3_A1*~ = 25, n~*slc6a3_A2*~ = 40, \*\*\*\*p \< 0.0001, significance test: one-way ANOVA Kruskal-Wallis test).(G) The quantification of duration of "digging" feature over the whole 30-min recording time in the tank using Janelia Automatic Animal Behavior Annotator (JABBA) ([@bib18]) (n~WT~ = 64, n~*slc6a3*\_A1~ = 25, n~*slc6a3*\_A2~ = 40, \*\*\*\*p \< 0.0001, significance test: one-way ANOVA Kruskal-Wallis test.)See [Figure S3](#mmc1){ref-type="supplementary-material"} for more details.Table 1gRNAs and Genotyping Primers for *slc6a3−/−* CRISPR KnockoutAllele1Allele2gRNAGGAGTACTAATTGAGGCCATCGGCGTTGAGGTCGGAGCAGTTTGGGGenotyping primer FGGAGTACTAATTGAGGCCATCGGCCTTCCCAGACGTCTTCACTCCTGenotyping primer RACTTGGGGAAATGTTCATCGTAGGGATCCTGATCTCGCTGTATGTGGTable 2Sequences of qRT-PCR PrimersForwardReverse*slc6a3-Q1*GGTTCAGTTCACCTCCTCCAACGGACAGCAGAAAGTCGAT*slc6a3-Q2*CCTTCCTCATCTCGCTCATCTCATCACTGAAGCGATCCAC*epoa*TGATGAAGCTTGTCCAGCACCAGCTTCCGAGAAAAACCTG*epor*GAGGACCAGCGTTCAGACTCGTGCGAGGCATTTAGAGAGG*nt5c2l1*TGGCGCTCTTACTTTGACCTCCTGTCGCTTCTTGGACTTC*bactin*CGAGCAGGAGATGGGAACCAACGGAAACGCTCATTGC

Video S1. Wild-type Behavior, Related to Figure 1

Video S2. *slc6a3−/−* allele1 Behavior, Related to Figure 1

Video S3. *slc6a3−/−* allele2 Behavior, Related to Figure 1

Midbrain Dopaminergic Neurons Degenerate in *slc6a3−/−* Fish {#sec2.2}
------------------------------------------------------------

*slc6a3* is expressed in the brain in the diencephalon, olfactory bulb, and pretectum ([@bib8], and [Figure S5](#mmc1){ref-type="supplementary-material"}A) in larvae and adult. Brain concentrations of dopamine in the *slc6a3−/−* fish are decreased by 16% compared with wild-type (*slc6a3−/− allele1*: 0.024 ± 0.001 nmol/mg tissue, wild-type: 0.030 ± 0.001 nmol/mg tissue) ([Figure 2](#fig2){ref-type="fig"}E). We therefore wondered if this decline in dopamine might reflect loss or dysfunction of dopaminergic neurons and so labeled cells for TH by immunohistochemistry. As a rate-limiting enzyme of dopamine biosynthesis, TH is often used as a marker for dopaminergic neurons ([@bib39]). We used the CUBIC clearing strategy to visualize TH+ neurons throughout the entire adult brain ([@bib37]). We find, as have others ([@bib31]), that TH+ neurons are concentrated in a few discrete clusters ([Figures 2](#fig2){ref-type="fig"}A and [S5](#mmc1){ref-type="supplementary-material"}B). *slc6a3* mutation causes reduction of TH+ neuron number and branching pattern, primarily limited to the midbrain areas termed A8 and A9 in 8-week-old fish brains ([Figures 2](#fig2){ref-type="fig"}B--2D, 2C′--D′, 2F, and [S5](#mmc1){ref-type="supplementary-material"}C). TH+ neuron loss in other brain areas was not detected ([Figure S5](#mmc1){ref-type="supplementary-material"}D). The A8 region of the zebrafish midbrain is believed to be homologous to the retrorubral field (RrF) region of mammals, and the A9 region, to the substantia nigra (SNc) ([@bib13]).Figure 2Midbrain Tyrosine Hydroxylase Immunoreactive (TH+) Neurons Degenerate in the *slc6a3−/−* Fish Brain(A and B) Sagittal view of 3-dimensional rendering of tyrosine hydroxylase (TH) immunostaining of the whole brains of (A) wild-type (WT) and (B) *slc6a3−/− allelle1* at 3 months post-fertilization. The arrows indicate two groups of TH+ neurons (A8 and A9 areas) in the midbrain and show reduction in cell numbers in the *slc6a3−/− allele1* compared with WT. Scale bar, 400 μm. a, anterior; p, posterior; d, dorsal; v, ventral.(C--E) (C and D) Representative images of TH+ neurons in (C and C′) WT and (D and D′) *slc6a3−/− allele1* fish brain in the A8 area at 2 months post-fertilization showing structural changes in neurons and diminution in their arborization. For visualization purpose, images are shown as horizontal ventral views, with anterior on the top. Five optical planes (6-μm interval) were stacked to show the TH+ cells. Scale bar, 20 μm. (E) Mass spectrometry of the dopamine level shows a significant reduction in the *slc6a3−/−* fish. n = 12 for both WT and *slc6a3−/− allele1*. \*\*p \< 0.01. Significance test: Wilcoxon-Mann-Whitney test.(F) Boxplot shows reduction in cell numbers of A8 TH+ neurons at 2 months post-fertilization.Error bar = standard deviation. n = 11 for both WT and *slc6a3−/−* allele1. \*\*p \< 0.01. Significance test: Wilcoxon-Mann-Whitney test.

Chronic Treatment with Clozapine Rescues Wild-Type Behavior and Midbrain TH+ Neurons {#sec2.3}
------------------------------------------------------------------------------------

We screened psychoactive compounds, especially those known to act at least in part by affecting dopamine signaling, upon the bottom-dwelling behavior of *slc6a3−/−* fish. We chose doses predicted to achieve, at final dilution in the water, concentrations of 1× or 5× the EC50 for dopamine receptors and assessed swimming behaviors over time ([Figure 3](#fig3){ref-type="fig"}A). Of the compounds, clozapine has the clearest effect on swimming behavior, although it takes at least 3 weeks to manifest ([Figures 3](#fig3){ref-type="fig"}B--3D). As shown in [Figure 3](#fig3){ref-type="fig"}C, clozapine exposure for 3 weeks causes the fish to resume swimming throughout the height of the tank and, as shown in the attached videos ([Videos S4](#mmc6){ref-type="supplementary-material"} and [S5](#mmc7){ref-type="supplementary-material"}), completely abrogates the repetitive "digging" behavior ([Figures 3](#fig3){ref-type="fig"}D and [S4](#mmc1){ref-type="supplementary-material"}). Thus, clozapine effectively restores the *slc6a3−/−* behaviors to wild-type.Figure 3Chronic Clozapine Treatment Rescues Aberrant Swimming Behavior and Midbrain TH+ Neurons in the *slc6a3−/−* Fish Brain(A) Schematic of the experimental design for chronic treatment of *slc6a3*−/− allele1 mutant fish with candidate compounds.(B) The heatmap of fish trajectories of control (DMSO) and 2.5 μM clozapine-treated *slc6a3−/−* allele1 fish after 3 weeks\' treatment showing that clozapine reverses aberrant "digging" behavior.(C) Time course of swimming height from week 0 (W0) to week 3 (W3) (n = 5; error bar = standard deviation).(D) The time course of the "digging" feature duration by all compounds over time (n = 5, error bar = standard deviation).(E--F) Representative images of TH+ neurons in (E and E′) DMSO and (F and F′) 2.5 μM clozapine-treated *slc6a3−/− allele1* fish brain in the A8 area at 3 months post-fertilization showing restoration of neuronal number and arborization by clozapine. For visualization purpose, images are shown as horizontal ventral views, with anterior on the top. Five optical planes (6-μm interval) were stacked to show the TH+ cells. Scale bar, 20 μm.(G) Boxplot shows clozapine-induced restoration of TH-immunoreactive A8 cell number in *slc6a3−/− allele1* fish at 3 months post-fertilization.(For all, n ≥10. Error bar = standard deviation. \*\*\*p \< 0.001, \*p \< 0.05. N.S., no significance. Significance test: one-way ANOVA Kruskal-Wallis test).

Video S4. *slc6a3−/−* allele1 Behavior with 3-Week DMSO Treatment, Related to Figure 3

Video S5. *slc6a3−/−* allele1 Behavior with 3-Week 2.5 μM Clozapine Treatment, Related to Figure 3

We also find that 3 weeks of exposure to 2.5 μM clozapine treatment rescues A8 (but not A9) TH+ neuronal number and morphology (3 months post-fertilization, [Figures 3](#fig3){ref-type="fig"}E--F′, 3E′--3F′, 3G, and [S5](#mmc1){ref-type="supplementary-material"}E--S5H). This is compatible with the A8 regional loss contributing to the unusual behavior of the mutant fish and suggests that clozapine may act, at least in part, by protecting this population of cells.

Erythropoietin Pathway as a Potential Clozapine Target {#sec2.4}
------------------------------------------------------

To begin to dissect pathways by which clozapine rescues the *slc6a3−/−* behavior we performed RNA-seq of the adult *slc6a3−/−* fish brains and compared clozapine with control treatment ([Table S1](#mmc2){ref-type="supplementary-material"}). Interestingly, levels of dopamine pathway genes are only modestly affected by clozapine treatment ([Figure S6](#mmc1){ref-type="supplementary-material"}A). The most significant changes in expression are in *erythropoietin a* (*epoa*, by 6.35 ± 1.62-fold) and *5′-nucleotidase*, *cytosolic II*, *like 1* (*nt5c2l1* by 5.73 ± 0.69-fold) ([Figures 4](#fig4){ref-type="fig"}A and 4B), the latter an enzyme that converts extracellular nucleotides, such as 5′-AMP, to nucleotides, such as adenosine. There are also significant increases in expression of *erythropoietin receptor* (*epor*, by 1.92 ± 0.54-fold) ([Figures 4](#fig4){ref-type="fig"}A and 4B). Quantitative RT-PCR of these genes independently confirmed the upregulation by clozapine ([Figure S6](#mmc1){ref-type="supplementary-material"}B, [Table 2](#tbl2){ref-type="table"}). We focused on the *epo* pathway because erythropoietin has been previously reported to have neuroprotective effects, particularly on midbrain dopaminergic neurons ([@bib29], [@bib33]). We generated a transgenic line stably expressing *epoa* in CNS neurons (driven by a neuronal alpha tubulin promoter, [Figures 4](#fig4){ref-type="fig"}C--4E), and which increases *epoa* expression levels by more than 2-fold ([Figure 4](#fig4){ref-type="fig"}F). When crossed into *slc6a3−/−* fish, their behavior was restored toward wild-type ([Figures 4](#fig4){ref-type="fig"}G and 4H, [Video S6](#mmc8){ref-type="supplementary-material"}), indicating that the clozapine-induced *epoa* expression may account for part of clozapine\'s effect in these fish.Figure 4RNA-Seq Analysis Reveals Erythropoietin Pathway as a Potential Clozapine Target(A) The volcano plot of log2-fold change of gene expression in the adult fish brain between the treatments of clozapine and DMSO in *slc6a3−/− allele1*. The clozapine highly upregulated genes (*epoa*, *epor*, and *nt5c2l1*) are indicated on the graph.(B) Bar plot of gene expression of *epoa*, *epor,* and *nt5c2l1* by RNA-seq analysis. \*\*\*\*p \< 0.0001, \*\*\*p \< 0.001. n = 8 for all. Error bar = standard deviation. Significance test: Wilcoxon-Mann-Whitney test.(C) The construct maps for over-expression of *epoa* in neurons with the tetracycline-controlled transcriptional activation system.(D and E) The dorsal view of the green channel (D) and bright field (E) of a *slc6a3^−/−\_allele1^; Tg(aTub:iTTA; TetO:EpoA-2a-GFP)* fish at 5 days post-fertilization under a fluorescent dissecting microscope. The brain area (indicated by green fluorescence in D) is outlined by a dotted line. Scale bar, 250 μm.(F) Whole-brain qRT-PCR at 2 months post-fertilization confirms the upregulation of *epoa* in the *slc6a3*^*−/−*\_*allele1*^;*Tg*(*aTub*:*iTTA*; *TetO*:*EpoA-2a-GFP*) fish. Error bar, standard deviation. n = 6 for all conditions. \*\*\*p \< 0.001, \*\*p \< 0.01, N.S., no significance. Significance test, Wilcoxon-Mann-Whitney test.(G and H) The quantification of The quantification of average swimming height (G) and duration of "digging" feature (H) of *slc6a3^−/−^*^\_^*^allele1^*; *Tg*(*aTub*:*iTTA*; *TetO*:*EpoA-2a-GFP*) compared to *slc6a3^−/−^*^\_^*^allele1^* and wild-type at 2 months post-fertilization.n~WT~ = 40, n*~slc6a3−/−\_allele1~*~\_~ = 20, n*~slc6a3−/−\_allele1~*~;~*~tg~*~(~*~aTub~*~:~*~eopa~*~)~ = 20. ^∗∗∗∗^p \< 0.0001, ^∗^p \< 0.05, N.S., no significance. Significance test: one-way ANOVA Kruskal-Wallis test.

Video S6. *slc6a3−/−* allele1; Tg(*aTub:iTTA; TetO:EpoA-2a-GFP*) Behavior at 2 Months Post Fertilization, Related to Figure 4

Discussion {#sec3}
==========

We find that homozygous loss of the dopamine uptake transporter, DAT (SLC6A3), causes zebrafish to manifest an unusual repetitive bottom-digging behavior, one reminiscent of sand digging of threatened sticklebacks ([@bib38]) and bottom searching by cave fish (*Astyanax mexicanus*) ([@bib35]). Thus, it may be part of a piscine behavioral repertoire, one exaggerated in zebrafish by the mutation. The behavior is accompanied by loss of particular set of midbrain TH+ neurons. Clozapine, an atypical antipsychotic, can restore wild-type behavior and neuronal morphology in one group of the TH neurons. Clozapine increases the expression of erythropoietin pathway genes, and transgenic over-expression of erythropoietin in neurons of *slc6a3−/−* fish can partially substitute for clozapine in restoring normal behavior.

DAT activity is the primary mechanism for ending dopaminergic transmission, keeping extracellular dopamine levels low, and restoring presynaptic levels. Genetic evidence indicates a role for DAT in both motor and cognitive functions. DAT is the target of the psychostimulants cocaine and amphetamine. In humans, complete loss of function of DAT in humans leads to infantile Parkinson disease, and partial loss, to late-onset dyskinesia ([@bib21], [@bib22]). DAT polymorphisms or changes in expression levels have been associated with several psychiatric and neurological disorders, including schizophrenia, ADHD, psychostimulant abuse, and Gilles de las Tourette syndrome ([@bib21], [@bib22]).

We noted no gross morphological change in the *slc6a3−/−* brain. This is consistent with the MRI scan in patients with DAT deficiency syndrome ([@bib28]). The most prominent effect we noted in the *slc6a3−/−* fish is neuronal loss and dysmorphology of TH-expressing neurons primarily in the A8 and A9 regions of the midbrain. These are believed to be homologous to RrF and SNc regions of the mammalian brain, respectively ([@bib1], [@bib31]). TH+ neurons of the SNc project to the caudate putamen and dorsolateral striatum, and their loss in Parkinson disease is believed to be responsible for the gait abnormalities in this disorder ([@bib1]). The TH+ neurons of the A8 homologous region, the RrF, project to the nucleus accumbens and the limbic cerebral cortex and have been proposed to be involved in emotion, reward, and cognitive function, and to be affected in a range of psychiatric disorders ([@bib1], [@bib12]). Abnormalities of both the nucleus accumbens and limbic cerebral cortex are implicated in schizophrenia pathology by postmortem human tissue analysis ([@bib17], [@bib27]). Interestingly, *slc6a3-*mutant mice manifest only minor reductions in TH-immunoreactive neurons in the striatum, the region most affected ([@bib7]). This may reflect a species difference, or it may be that, as in the fish, it is only a small subpopulation of specific neurons that are lost in the mouse.

Clozapine was synthesized originally with the goal of avoiding the extrapyramidal side effects of earlier antipsychotic drugs, assumed accomplished by diminishing its D2 activity. However, it is clear that its therapeutic mechanism is unlikely to be explained solely by its effect upon the dopamine system, because it also enhances the activity at serotonin 2A receptor and several other receptors ([@bib5]). Clozapine\'s use is compromised by rare but life-threatening agranulocytosis, and more common weight gain, so understanding its mechanism of action is critical to the development of efficacious and safer therapeutics. The zebrafish brain can regenerate neurons in response to injury ([@bib9], [@bib14]), and it is certainly conceivable that human responses to clozapine might not include the dramatic repair that we see here.

We find that *epoa* and *epo* receptors are among the genes whose expressions are most increased by clozapine and that transgenic *epoa* expression in neurons can mirror clozapine\'s restorative effect on behavior. These observations are of interest because, in addition to its well-defined role in erythropoiesis, the Epo pathway has been proposed as neuroprotective in a variety of CNS disorders, including ischemia, traumatic brain injury, Parkinson disease, and schizophrenia ([@bib20], [@bib33]). In the CNS, EpoRs are expressed by neurons, glia, and endothelial cells, especially during embryonic development ([@bib29]). Mice lacking Epo or its receptor have defective neurogenesis during development ([@bib29]). Adult TH+ neurons express EpoR, and Epo can rescue neurons from 6-hydroxydopamine toxicity, both *in vitro* and *in vivo* by CNS infusion ([@bib33]). It is believed that Epo actions in the CNS are mediated by a heterodimer of the EpoR and CD131, rather than via the homodimer responsible for Epo activation of erythropoiesis ([@bib33]). Mutation of *slc6a3* does not by itself affect *epoa* levels, so we presume that Epo is not in the pathway directly affected by *slc6a3* mutation and that salvage by transgenic over-expression of Epo is likely to act by a pathway parallel to that perturbed in *slc6a3−/−* fish.

We speculate that damage to TH+ neurons in the A8 (and A9) region of the zebrafish midbrain is responsible for the bottom-digging-like repetitive behavior of the *slc6a3−/−* fish, and that clozapine rescue of the A8 neural cells is responsible for restoring their behavior toward that of wild-type. Interestingly, we do not see significant rescue of A9 by clozapine treatment. Of course, we cannot determine whether the rescue of TH+ neurons also accounts for clozapine\'s therapeutic effect in humans, although the areas perturbed in schizophrenia include those believed homologous to projection zones of A8-equivalent (i.e., RrF) DA neurons. In addition, the similar restorative effect exerted by erythropoietin expression suggests that this might be a novel pathway to explore for discovery of new medicines with clozapine-like therapeutic activities.

Limitations of the Study {#sec3.1}
------------------------

The observations suggest that the behavioral disorder may be due to A8 neuronal dysfunction, but proof will require specific targeting of such neurons, unfortunately technically non-trivial because the midbrain is relatively deep in animals old enough to manifest this behavioral phenotype.

We have focused upon the Epo pathway as one potential intermediary in the clozapine effect. Transgenic *epoa* expression rescues behavior in *slc6a3−/−* animals, but not to the same degree as clozapine, suggesting that we may need to target more precisely or that it explains only part of clozapine\'s effect. Along these lines it would be of interest to mutate *epoa* to see if such mutation generates behavior akin to that seen in *slc6a3−/−* fish, but the critical role of Epo in hematopoiesis causes early death in such animals. Genes other than *epoa* are regulated by clozapine and could be important. For example, there is an increase in 5′-nucleotidase (an enzyme that converts extracellular nucleotides, such as 5′-AMP, to nucleotide, such as adenosine), the activity of which is known to increase after clozapine treatment in humans and in the rat ([@bib4], [@bib24]).

Methods {#sec4}
=======

All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.

Supplemental Information {#appsec2}
========================

Document S1. Transparent Methods and Figures S1--S6Table S1. Normalized RNA-Seq Counts of All Genes in *slc6a3−/−* allele1 Treated by DMSO and 2.5 μM Clozapine, Related to Figure 4
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